Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04184726
Other study ID # 266101
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 9, 2020
Est. completion date September 30, 2022

Study information

Verified date January 2022
Source Guy's and St Thomas' NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a research study on Mindfulness-Based Cognitive Therapy for visual symptoms (MBCT-vision), to treat patients with debilitating symptoms of visual snow (VS) and is associated visual symptoms, severe light sensitivity (i.e. photophobia) and migrainous visual aura. Participants will receive an intervention of an 8-week MBCT course modified for visual symptoms, which will involve 8 weeks of once weekly group sessions and home practice between sessions.


Description:

This is a research study on Mindfulness-Based Cognitive Therapy for visual symptoms (MBCT-vision), to treat patients with debilitating symptoms of visual snow (VS) and its associated visual symptoms, severe light sensitivity (i.e. photophobia) and migrainous visual aura. VS is a condition of persistent flickering dots, like that of an out-of-focus analog television screen, affecting the whole visual field. There can be associated visual symptoms such as after-images, and trailing of images. No clinical trials for treatment have been done for VS. Instead, treatment data comes from patient case reports. Photophobia describes discomfort or pain to light stimulation. Causes include eye surface issues, migraine, or of an unknown trigger, and can be persistent despite optimum management of underlying causes. Patients with migrainous visual aura may have troublesome visual disturbances despite optimum migraine treatment. Previous studies have shown that dysfunction in brain pathways contribute to the above conditions. Mindfulness-Based Cognitive Therapy is a treatment that combines evidence-based approaches of Mindfulness-Based Stress Reduction and Cognitive Behavioural Therapy (CBT). MBCT is an established 8-week programme designed to develop skills of mindfulness and CBT strategies in individuals, through weekly small-group sessions and structured daily practice between sessions. Studies on MBCT and mindfulness-based interventions have shown improvements in psychological resilience; physical health including immune function; and neural changes associated with psychological wellbeing. The investigators propose that MBCT, modified to incorporate aspects relevant to persistent and distressing visual symptoms (MBCT-vision), can improve these debilitating symptoms by modifying dysfunctional neural pathways and equip patients with skills that promote psychological resilience and improve coping with residual symptoms. For this study, the investigators will assess the use of MBCT-vision in patients with visual snow or associated visual symptoms, migrainous visual aura or photophobia. This will be the first study of a mindfulness-based intervention in this population.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date September 30, 2022
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria: - Patients with visual snow or associated visual symptoms; photophobia for at least 3 months - Patients with migrainous visual aura occurring >4 episodes a month for at least 3 months Exclusion Criteria: - Patient with a current severe depressive or psychotic episode - Patient with severe difficulties in emotional regulation - Patient unable to provide informed consent for participation - Patient with insufficient understanding of spoken English (due to need to participate in group discussions)

Study Design


Intervention

Behavioral:
Mindfulness Based Cognitive Therapy
mindfulness and cognitive behavioural therapy techniques taught in group sessions meeting once weekly for 8 weeks, and home practice between sessions.

Locations

Country Name City State
United Kingdom Guys & St Thomas' NHS Foundation Trust London

Sponsors (1)

Lead Sponsor Collaborator
Guy's and St Thomas' NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary change in severity of visual symptoms change in severity of visual symptoms pre- and post-intervention, comparing scores on Likert scale, ranging from 0/10 (no symptoms) to 10/10 (extremely severe symptoms) week 9 and 20
Secondary change in World Health Organisation (WHO) wellbeing index scores change in WHO wellbeing index, comparing pre- and post- intervention scores. WHO wellbeing index range from 0-25, with higher scores representing increased wellbeing. week 9 and 20
Secondary change in Clinical Outcomes in Routine Evaluation (CORE-10) scores change in CORE-10 scores, comparing pre- and post- intervention. CORE-10 scores range from 0-40 with higher scores indicating more distress. week 9 and 20
Secondary change in Five-Facet Mindfulness Questionnaire (FFMQ) scores change in Five-Facet Mindfulness Questionnaire scores, comparing pre- and post- intervention. FFMQ scores range from 39-195 where higher scores represent more mindfulness week 9 and 20
Secondary compliance (session attendance and completion of daily practice) participant compliance from attendance record for MBCT-vision weekly sessions and self-report compliance with daily home practice week 9
Secondary qualitative assessment of MBCT-vision participant feedback on the design of MBCT-vision via structured qualitative interview week 9
Secondary functional MRI changes to functional MRI comparing baseline to week 20 - this has been added for participants recruited in the second and third cohort week 20
See also
  Status Clinical Trial Phase
Completed NCT06159569 - Performance and Tolerability of the Medical Device LACRIACT N/A
Completed NCT00330850 - An Efficacy Study of a Single Dose Treatment of PRO-513 for Subjects Suffering a Migraine Attack Phase 3
Recruiting NCT05829135 - Improving Glare and Visual Comfort for Patients With Visual Impairment N/A
Completed NCT01828684 - Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Patients With Migraine N/A
Active, not recruiting NCT05207865 - Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention Phase 4
Recruiting NCT03464357 - Functional MRI Study of Cortical Modifications to Light Stimulation in Patients With Photophobia N/A
Recruiting NCT03694626 - Objectively Diagnose and Monitor Treatment of Light Sensitivity N/A
Terminated NCT01942486 - Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Child and Adolescent Patients With Migraine N/A
Recruiting NCT06109909 - Pilot Study of Neurofeedback for Photosensitivity in Mild Traumatic Brain Injury N/A
Not yet recruiting NCT06149000 - Migraine Headache Mitigation Utilizing Avulux N/A
Completed NCT01942564 - The Head Injury-associated Photosensitivity and Pupillary Function (HIPP) Study N/A
Withdrawn NCT02837523 - Biomarker for Cystinosis Disease: BioCystinosis (BioCystinosis)
Completed NCT05369910 - How Can we Treat Photophobia in Migraine N/A